Street Calls of the Week
Investing.com - BMO Capital has reiterated its Market Perform rating and $50.00 price target on Sarepta Therapeutics (NASDAQ:SRPT). According to InvestingPro analysis, the stock appears undervalued at current levels, with analyst targets ranging from $5 to $80.
The firm’s decision comes as Sarepta stock has fallen approximately 85% year-to-date, compared to a 4% gain in the XBI biotech index, following two non-ambulatory patient deaths that raised concerns about the viability of its Elevidys therapy.
Despite these concerns, BMO Capital notes that the market has largely removed Elevidys from Sarepta’s valuation, with the company’s market capitalization now at approximately $1.7 billion. The company maintains a healthy current ratio of 2.89, though InvestingPro data shows it’s trading at a relatively high EV/EBITDA multiple of 51x.
A survey of 30 physicians conducted by BMO Capital revealed that about 90% of physicians continue prescribing Elevidys following the patient deaths, with approximately 35% prescribing it at a similar rate as before the incidents.
The survey also found that in a scenario where an ambulatory Elevidys patient death occurs—described as the biggest current risk for Sarepta—more than 40% of physicians would still continue prescribing the therapy without waiting for safety updates.
In other recent news, Sarepta Therapeutics announced a significant financial maneuver involving the exchange of $700 million in convertible senior notes due in 2027. The company entered into agreements to issue $602 million in new 4.875% convertible notes due in 2030, along with 5,851,693 shares of common stock and approximately $123.3 million in cash. This move is part of Sarepta’s broader refinancing strategy, which also includes reducing its overall debt by approximately $123 million. Analysts have weighed in on these developments, with H.C. Wainwright reiterating a Sell rating, citing the transaction as a net negative for equity holders due to modest debt reduction and nearly 10% dilution. Mizuho maintained a Neutral rating, although it lowered its sales forecast for Sarepta’s Elevidys product. Meanwhile, BofA Securities adjusted its price target for Sarepta, lowering it to $16 while maintaining an Underperform rating. These recent developments reflect the company’s ongoing efforts to manage its financial obligations and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.